Abemaciclib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1301 publications

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Feasibility Study on Development of a Collaborative Monitoring System between a Hospital and Community Pharmacy Using an Electronic Patient-Reported Outcome Application for Breast Cancer Outpatients Treated with Abemaciclib.

Feasibility Study on Development of a Collaborative Monitoring System between a Hospital and Community Pharmacy Using an Electronic Patient-Reported Outcome Application for Breast Cancer Outpatients Treated with Abemaciclib.

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: April 01, 2026

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Journal: bioRxiv : the preprint server for biology

Published: March 27, 2026

Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America.

Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America.

Journal: JCO global oncology

Published: March 19, 2026

Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy.

Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: March 05, 2026

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Journal: Journal of pharmaceutical policy and practice

Published: February 23, 2026

Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancer.

Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancer.

Journal: Wiener klinische Wochenschrift

Published: February 09, 2026

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

Journal: International journal of molecular sciences

Published: January 25, 2026

Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.

Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.

Journal: Cureus

Published: January 18, 2026

The Efficacy of CDK4/6 Inhibitors as Late Therapy in Patients Treated with Palbociclib and Abemaciclib Two Sequentially

The Efficacy of CDK4/6 Inhibitors as Late Therapy in Patients Treated with Palbociclib and Abemaciclib Two Sequentially

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 17, 2026

Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors.

Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors.

Journal: Science advances

Published: January 16, 2026

Showing 1-12 of 1,301

Last Updated: 04/28/2026